Description
Acalabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It showed increased selectivity compared with first generation BTK inhibitors such as ibrutinib while offering similar antitumor efficacy in mouse models of chronic lymphocytic leukemia. It has been approved for the treatment of patients with relapsed mantle cell lymphoma(MCL), a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. It is currently being investigated as a front line treatment for MCL.